Conditions: Schizophrenia
Keywords: H3 Antagonist Schizophrenia double blind Histamine randomised placebo controlled Cognition
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 50
Healthy volunteers: no

Brief summary:
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia

Detailed description:
This is a 7-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group design study in male and female subjects with schizophrenia who are stabilised on antipsychotic medication. Subjects will be randomised to receive either GSK239512 or placebo for 7 weeks. They will undergo weekly review of safety, tolerability and cognitive performance measures.

Arms:
arm 1: Repeat dose. arm 2: Repeat dose. Placebo to match GSK239512

Interventions: intervention 1: GSK239512 intervention 2: Placebo
Intervention descriptions: intervention 1: Histamine H3 Antagonist intervention 2: Placebo to match GSK239512

Protocol document: